	US 11,857,527 B2
	Medium chain triglyceride compositions
Bernard Cuenoud, Cully (CH); and Mojgan Masoodi, Ecublens (CH)
Assigned to Societe des Produits Nestle S.A., Vevey (CH)
Filed by Société des Produits Nestlé S.A., Vevey (CH)
Filed on Jan. 26, 2021, as Appl. No. 17/158,328.
Application 17/158,328 is a division of application No. 15/780,492, abandoned, previously published as PCT/EP2016/079521, filed on Dec. 2, 2016.
Claims priority of application No. 15197934 (EP), filed on Dec. 4, 2015.
Prior Publication US 2021/0145782 A1, May 20, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/21 (2006.01); A23K 20/158 (2016.01); A23L 33/12 (2016.01)

CPC A61K 31/21 (2013.01) [A23K 20/158 (2016.05); A23L 33/12 (2016.08); A23V 2002/00 (2013.01)]

14 Claims

1. A method of treating an individual having a brain energy deficiency condition or disease, the method comprising administering a composition comprising medium-chain triglycerides (MCTs) to the individual, wherein the MCTs comprise:

a MCT comprising three fatty acid moieties each with 8 carbon atoms (MCT-C8); and

a MCT comprising three fatty acid moieties each with 10 carbon atoms (MCT-C10);

wherein the ratio of the MCT-C8 to the MCT-C10 is from 10:90 to 90:10 (mol/mol), wherein at least 95 mol % of the MCTs in the composition are MCT-C8 and MCT-C10, and

wherein the composition provides increased ketones and/or fatty acids as compared to a composition comprising MCTs comprising three fatty acids moieties each with a mix of C8 and C10 moieties attached and having the same C8/C10 ratio and molar amounts.